Healthcare Industry News: Leksell Gamma Knife
News Release - October 15, 2010
Elekta to Highlight Latest Gamma Knife Surgery Innovations at Annual Neurosurgery ConferenceHypofractionated radiosurgery and treatment planning enhancements in the spotlight at Congress of Neurological Surgeons meeting
SAN FRANCISCO, Oct. 15 -- (Healthcare Sales & Marketing Network) -- Elekta will showcase updates to its Leksell GammaPlan® 10.0* treatment planning software for Leksell Gamma Knife® and the Extend™ program for Leksell Gamma Knife® Perfexion™ at the 2010 Congress of Neurological Surgeons (CNS) Annual Meeting, October 16-21 at the Moscone Convention Center in San Francisco. The Extend program dramatically broadens the types of cases for which clinicians can use Perfexion.
On the show floor, Elekta booth #109 will feature hands-on demonstrations of Extend, which combines patient-friendly head immobilization technology and stereotactic localization methods to permit hypofractionated Gamma Knife treatments for larger tumors or lesions close to critical structures located in the brain, skull base and other head and neck regions.
Updates to GammaPlan 10.0 include the two optional add-ons Inverse Planning and Convolution. Inverse Planning provides a fast, easy solution for Gamma Knife surgery planning, providing more reliable dose planning. The Convolution add-on is designed to increase confidence in the dose distribution and helps provide the optimum dose for heterogeneities in the skull.
Other meeting highlights
A leader and pioneer in neurosurgical solutions for decades, Elekta also will exhibit products that have set the standard for precision and efficiency in neurosurgical interventions and diagnosis, including:
- Elekta Axesse™, a fully integrated stereotactic system that combines 3D target visualization at time of treatment, 6D sub-millimeter robotic patient positioning and high-resolution beam shaping, making it a versatile treatment system perfectly suited for spine radiosurgery and neuro-oncology.
- Elekta Neuromag®, a magnetoencephalography (MEG) that moves beyond conventional imaging and clinical neurophysiology tools to provide clinicians and researchers with precise millisecond resolution and accurate localization to open a new window into human brain activity.
- Leksell Stereotactic System®, a complete stereotactic system that offers the level of accuracy and reliability required to perform diagnostic and therapeutic procedures with ease and confidence. The largest stereotactic user group in the world, more than 1,800 systems are in use at more than 1,300 treatment and training sites.
- SonoWand Invite™, an intracranial, intra-operative imaging system that provides real-time image clarity and spatial accuracy throughout surgery, allowing the surgeon to perform complicated tumor resections and vascular procedures safely, and with confidence the job is complete.
*Leksell GammaPlan® 10.0 is not yet cleared for sale in the United States.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible.
Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.
Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.